Catena Biosciences is focused on revolutionizing antibody-drug conjugates (ADCs) with its CysTyr™ Conjugation Platform, enabling the creation of Multi-Payload Conjugates (MPCs) that deliver dual payloads for treating solid tumors
Catena Biosciences is focused on revolutionizing antibody-drug conjugates (ADCs) with its CysTyr™ Conjugation Platform, enabling the creation of Multi-Payload Conjugates (MPCs) that deliver dual payloads for treating solid tumors.
Catena Biosciences is focused on revolutionizing antibody-drug conjugates (ADCs) with its CysTyr™ Conjugation Platform, enabling the creation of Multi-Payload Conjugates (MPCs) that deliver dual payloads for treating solid tumors
Catena Biosciences is focused on revolutionizing antibody-drug conjugates (ADCs) with its CysTyr™ Conjugation Platform, enabling the creation of Multi-Payload Conjugates (MPCs) that deliver dual payloads for treating solid tumors.